Gene Therapy for Blood Disorders Market is expected to Observe Considerable Growth Opportunities to 2031

Gene Therapy for Blood Disorders Market worth US$ 5.79 Billion by 2030 - Exclusive Report by InsightAce Analytic

The newly published report titled "Global Gene Therapy for Blood Disorders Market- By Trends, Industry Competition Analysis, Pipeline Analysis/Clinical Trial, Revenue (US$ Billions) and Forecast Till 2030." features in-depth analysis and an extensive market study, exploring its significant upcoming years industry factors.

According to the latest gene therapy industry market research report, the global gene therapy for blood disorders market size was valued at US$ 1.13 Billion in 2021, and it is expected to reach US$ 5.79 Billion in 2030, recording a promising CAGR of 21.6 % during the forecast period of 2022 to 2030.

Get Free Access to Demo Report, Excel Pivot and ToC: www.insightaceanalytic.com/request-sample/2521

genes can be changed using genetic therapy to treat illnesses. cell diseases are two rare blood disorders that it has great potential to address. combat uncommon diseases, some biopharma companies are turning to the CRISPR-Cas9 gene-editing method. with Vertex Pharmaceuticals, CRISPR Therapeutics is implementing a phase I/II trial of CTX001, a genetic treatment based on CRISPR/Cas9, to treat sickle cell disease. market is anticipated to rise in the next years due to a number of factors, including the rising incidence of blood and genetic disorders, the strong desire for personalized treatment, rising healthcare costs, and increased research and development efforts to provide new genetic therapies for hematology . cell anemia cases are expected to rise by roughly 30% globally, per a study published in the PLOS Medicine Journal. One of the main factors propelling this market is the rise in uncommon hematological illnesses.
it is anticipated that during the projected period, the high expense of gene therapy treatment and the possible adverse consequences of the medicines will impede its uptake.

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

The prominent players in the gene therapy for blood disorders industry include:
BioMarin Pharmaceutical Inc. (U.S.), Medgenics (U.S.), Spark Therapeutics (U.S.), bluebird bio, Inc. (U.S.), Shire (U.S.), CRISPR Therapeutics (U.S.), Freeline Therapeutics (U.K.), OrphageniX (U.S.), Errant Gene Therapeutics (U.S.), Sangamo Therapeutics (U.S.), Sigilon Therapeutics, Inc. (U.S.), uniQure (Netherlands), Angiocrine Bioscience (U.S.), and Sanofi Genzyme (U.S.), and other prominent players.

Gene Therapy for Blood Disorders Market Regional Analysis:
North America is predicted to account for the largest share of the gene therapy for blood disorders market during the forecast years, followed by Europe, owing to the rising prevalence of various blood disorders, well-developed healthcare systems, and increasing R&D investments to develop effective gene therapies to treat rare diseases. According to the Hemophilia Federation of America, Hemophilia affects 1 in 5,000 male births, and around 400 babies are born with hemophilia in the U.S annually. Worldwide 400,000 individuals are living with hemophilia, and approximately 20,000 people are living with it in the United States alone.

Unlock Your GTM Strategy: www.insightaceanalytic.com/customisation/2521

The Global Gene Therapy for Blood Disorders Market Segments

Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2021 to 2030 based on Indication
• Sickle Cell Anemia
• β-thalassemia
• Hemophilia B
• Hemophilia A
• Other Indication

Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2021 to 2030 based on Mechanism of Action
• Gene Therapy
• Gene Editing

Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2021 to 2030 based on Region
• Europe
• North America
• Latin America
• Asia Pacific
• Middle East & Africa
North America Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
• U.S.
• Canada
Europe Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
• Germany
• Spain
• France
• Russia
• Italy
• Rest of Europe
Asia Pacific Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
• India
• Japan
• China
• Australia & New Zealand
• South Korea
Latin America Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
• Brazil
• Mexico
• Rest of Latin America

The Middle East & Africa Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
• South Africa
• GCC Countries
• Rest of the Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ www.insightaceanalytic.com/buy-report/2521

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.